Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690885 | 0.88 | POLB (0.62) | ADORA2AADORA1TP53BPTFPOLB | |
| SCHEMBL19691028 | 0.86 | ADORA2A (0.56) | ADORA2AADORA1TP53BPTFPOLB | |
| SCHEMBL19690896 | 0.86 | ADORA2A (0.55) | ADORA2AADORA1TP53BPTFPOLB | |
| SCHEMBL19690954 | 0.85 | ADORA2A (0.56) | ADORA2AADORA1TP53BPTFPOLB | |
| SCHEMBL19691024 | 0.84 | BPTF (0.43) | ADORA2AADORA1BPTFPOLBALOX15 | |
| SCHEMBL19690943 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1TP53POLBLMNA | |
| SCHEMBL19690984 | 0.82 | ADORA2A (0.55) | ADORA2AADORA1POLBALOX15MAPT | |
| SCHEMBL19690839 | 0.80 | ADORA2A (0.53) | ADORA2AADORA1POLBALOX15MAPT | |
| SCHEMBL19690833 | 0.80 | ADORA2A (0.52) | ADORA2AADORA1TP53POLBLMNA | |
| SCHEMBL19690944 | 0.78 | ADORA2A (0.55) | ADORA2AADORA1POLBALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1792/4885ADORA1 965/4885TP53 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.